Global Impact

Point-of-Care Testing: Our device’s potential for point-of-care testing means it can be used in various settings, including remote and rural areas, without the need for sophisticated laboratory infrastructure. This can lead to more widespread and immediate diagnostic testing, reducing the time to diagnosis and treatment.

Enhanced Disease Detection: By refining the detection limits and improving sensitivity, our lateral flow assay could enable earlier and more accurate detection of diseases, such as pancreatic cancer. This can lead to timely interventions and significantly improve patient survival rates and outcomes.

Improved Accessibility and Affordability: Developing a cost-effective and accessible diagnostic tool could democratize healthcare, making advanced diagnostic capabilities available to underserved populations, particularly in resource-limited environments.

Scalability and Practical Application: Transitioning from gel electrophoresis-based assays to our novel lateral flow method would make large-scale studies and routine diagnostics feasible. This could lead to widespread adoption in clinical settings, enhancing the overall efficiency and effectiveness of disease management.

Advancement in Autodigestion Research: The ability to monitor protease activity at the point-of-care with our assay would significantly support research into autodigestion processes. This could lead to a better understanding of various pathological conditions and the development of new therapeutic strategies.

Tram